MedImmune starts CAIV-T Phase III

MEDI began an international, double-blind Phase III trial of its CAIV-T second-generation intranasal influenza vaccine

Read the full 156 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE